Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

Inclusion Criteria

• •Patients with a diagnosis (\> 3 months prior to enrollment) of:
• •* Chronic myeloid leukemia (CML) (Philadelphia chromosome positive or polymerase chain reaction \[PCR\] positive for breakpoint cluster region \[BCR\]-Abelson murine leukemia viral oncogene homolog 1 \[ABL\]) in chronic phase with:
• •* Persistent or progressive disease on maximum tolerated interferon therapy, or STI571 (if eligible and able to receive this drug), as evidenced by increasing white blood cell (WBC) count, peripheral blood myeloid immaturity and/or progressive anemia, and/or persistence or relapse of abnormal cytogenetic and/or molecular findings
• •* Interferon or STI571 intolerant
• •* CML (Philadelphia chromosome positive or PCR positive for BCR-ABL) in accelerated phase (\< 20% blasts in the peripheral blood and bone marrow) with persistent or progressive disease on STI571 (if eligible and able to receive this drug)
• •Chronic myelomonocytic leukemia (CMML)
• •* Proliferative-type (WBC \> 12,000/mL)
• •* Less than 5% blasts in the peripheral blood and \< 20% blasts in the bone marrow
• •Undifferentiated myeloproliferative disorder (UMPD)
• •Atypical (i.e. Philadelphia chromosome-negative) CML
• •Four weeks must have elapsed since the use of any previous pharmacotherapy including interferon, hematopoietic growth factors, and cytotoxic chemotherapy (6 weeks for prior mitomycin or nitrosoureas); hydroxyurea may be used to manage elevated cell counts in patients up to the time they begin investigational therapy
• •Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• •Patients are capable of swallowing capsules
• •Total bilirubin is \> 1.5 X the upper limit of normal (ULN) where the analysis is performed; for example, for Stanford University Hospital, the ULN for total bilirubin is 1.3
• •Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) are \> 2 X the ULN; for example, for Stanford University Hospital, the ULN for ALT is 35, and the ULN for AST is 41
• •Serum creatinine of \< 2.0
• •Life expectancy \> 4 months
• •Written inform consent must be obtained